MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.060 -0.010 (-0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
The Latest Analyst Ratings for Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Stock Soared 12% Higher Today ↗
A business, clinical, and regulatory update lifted the spirits of investors. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today? ↗
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying. 
Via InvestorPlace
News headline image
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
 
Via Benzinga
News headline image
Recap: Iovance Biotherapeutics Q3 Earnings ↗
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points ↗
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
News headline image
Iovance Biotherapeutics Stock Is Surging: Here's Why ↗
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock ↗
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on... 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Is Crashing Today ↗
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate ↗
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
News headline image
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Preview: Iovance Biotherapeutics's Earnings ↗
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story